Filters

Latest News

2018-01-18 06:30:28

Report shows life sciences industry alliance is taking action to curb antimicrobial resistance, with more to come

The new AMR Industry Alliance of more than 100 biotech, diagnostics, generics and research-based biopharmaceutical companies and trade associations launches ...

Read More

2017-12-15 08:00:20

Greg Perry Joins International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) as new Assistant Director General

Geneva, 15th December 2017 – IFPMA, the global research-based biopharmaceutical industry association, today announced the ...

Read More

2017-12-14 00:40:34

Pharma supports “Reaching a Billion – ending Neglected Tropical Diseases Gateway to UHC” report and call to action

Pharma supports “Reaching a Billion – ending Neglected Tropical Diseases Gateway to UHC” report and ...

Read More

2017-12-13 08:42:44

10th annual G-FINDER report: Pharmaceutical industry R&D investment funding for neglected diseases continues to be a good news story

10th annual G-FINDER report: Pharmaceutical industry R&D investment funding for neglected diseases continues to be ...

Read More

2017-11-28 11:10:07

Press Release: 3rd Biennial Scientific Conference on Medical Products Regulation in Africa

*3rd Biennial Scientific Conference on Medical Products Regulation in Africa* PRESS RELEASE, 27 November 2017, ...

Read More

2017-11-01 13:52:03

IFPMA names new Communications Director

Appointment Release International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) names new Communications Director   ...

Read More

2017-10-26 10:06:43

Global coalition in the fight against falsified medicines meets in Brussels as it welcomes its 35th partner

Wednesday, 25 October 2017, Brussels – Fight the Fakes campaign partners representing healthcare professionals, academia, ...

Read More

Latest Statement

2017-11-22 15:24:27

International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Statement EB Special session on the draft Thirteenth General Programme of Work

International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Statement EB Special session on the draft Thirteenth General Programme of Work ...

Read More

2017-10-13 08:31:02

Contribution to the public web-based consultation on the Draft concept note towards WHO’s 13th General Programme of Work 2019–2023

Wednesday, 25 October 2017, Brussels – Fight the Fakes campaign ...

Read More

2017-10-12 08:28:56

IFPMA-EFPIA Statement - Global call for action on drug-resistant infections, 12-13 October 2017, Berlin (Conference organized by Wellcome Trust)

Wednesday, 25 October 2017, Brussels – Fight the Fakes campaign ...

Read More

2017-10-12 08:25:01

AMR Industry Alliance Statement - Global call for action on drug-resistant infections, 12-13 October 2017, Berlin (Conference organized by Wellcome Trust)

Wednesday, 25 October 2017, Brussels – Fight the Fakes campaign ...

Read More

2017-10-05 16:00:53

IFPMA Statement at WIPO 2017 General Assemblies

Wednesday, 25 October 2017, Brussels – Fight the Fakes campaign ...

Read More

2017-08-30 16:15:35

IFPMA Statement on UHC at 67th Session of the WHO Regional Committee for Africa

Wednesday, 25 October 2017, Brussels – Fight the Fakes campaign ...

Read More

2017-08-30 14:33:29

IFPMA Statement on Yellow Fever at 67th Session of the WHO Regional Committee for Africa

Wednesday, 25 October 2017, Brussels – Fight the Fakes campaign ...

Read More

mailto:s.kaenzig@ifpma.org +41 22 338 32 49
direct line
Twitter skaenzig

Sadia Kaenzig - Communications Manager

Sadia manages communications on issues including regulatory, intellectual property protection, trade and the economic footprint of the research-based pharmaceutical industry, research and development ecosystem and innovation, vaccines including influenza vaccines, and biotherapeutics.

mailto:m.depol@ifpma.org +41 22 338 32 20
direct line
Twitter @MorganePol

Morgane De Pol - Communications and Public Affairs

Morgane manages communications on issues including the research-based pharmaceutical industry’s commitment to achieving sustainable and inclusive development, advancing Universal Health Coverage, designing transformational partnerships to build healthier societies, boosting innovation for neglected tropical diseases, expanding access to high quality treatments for infectious and chronic diseases, fighting counterfeit medicines, and promoting resilient and efficient health systems.

A shared commitment to global health

Our Brouchure

2015 Edition

A shared commitment to global health

At IFPMA we advocate policies and practices that encourage the discovery of and access to life-saving and life-enhancing medicines and vaccines, for people everywhere.


Our Logo

Full colour EPS format

Our Logo

Full colour PNG format


FULL Name LOGO

Full colour EPS format


FULL Name LOGO

Full colour PNG format

Hot Topic

Pharmacovigilance: Do your bit, play your part!

Pharmacovigilance is one of the key steps to ensuring the safety of all our medicines, including biotherapeutics and vaccines. It encourages an ongoing cycle of communication between patients, health professionals, regulatory authorities, and our biopharma industry which is

Read More

Interview

IFPMA 2015 interview series 'Biodiversity, human health, and pharma'

A must-watch: Dr Manisha A. Desai, assistant general patent counsel at Eli Lilly and Company, gives her take on the importance of the Convention of Biodiversity and the Nagoya Protocol for the pharma industry. What's key is to

Read More

Our Blog

Latest Tweets

Come and join us @IHEID & @CHGlobalHealth & @IFPMA on Tuesday 23 January to hear more about the future of health in… https://t.co/Ujad3e0V7z
7 8
  @IFPMA
RT @AMRAlliance: In our survey, 90% of companies view current R&D incentives as “insufficient” or “far to go”. Here’s @IFPMA DG @ThomasCuen…
2
  @IFPMA
11 out of 11 large R&D pharma members responded to the @AMRAlliance survey on what actions they are taking to… https://t.co/6sooNGx51P
  @IFPMA
RT @ipwatch: Now on IPW: Industry Alliance Report: Companies Invest In AMR R&D, Need More Pull Incentives https://t.co/IBlIuaEPXd
3
  @IFPMA
22 @AMRAlliance members invested USD 2bn in 2016 in AMR-relevant products. Sustainable pull incentives to research… https://t.co/TtmSTzQRvM
1
  @IFPMA